Common Terminology Criteria for Adverse Events (CTCAE) v5.0 - Hematologic

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۲۵ • واحد: g/dL

حداقل ۰ — حداکثر ۵۰۰۰۰ • واحد: cells/mm³

حداقل ۰ — حداکثر ۲۰۰۰۰۰۰ • واحد: cells/mm³

حداقل ۰ — حداکثر ۵۰۰۰۰۰ • واحد: cells/mm³

حداقل ۰ — حداکثر ۵۰۰۰۰ • واحد: cells/mm³

حداقل ۳۰ — حداکثر ۴۵ • واحد: °C

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
ctcae grade
—grade
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Grade 00–0
  • Grade 11–1
  • Grade 22–2
  • Grade 33–3
Direct Clinical Answer

The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 - Hematologic calculator is designed for bedside assessing anemia, neutropenia, thrombocytopenia, and other blood disorders according to laboratory values and clinical presentations in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting systemic antineoplastic.

Clinical Guidelines & Evidence

Grades severity of hematologic and lymphatic adverse events from cancer treatment using standardized criteria. Assesses anemia, neutropenia, thrombocytopenia, and other blood disorders according to laboratory values and clinical presentations.

Clinical Indication

The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 - Hematologic is indicated for bedside clinical practice to support Grades severity of hematologic and lymphatic adverse events from cancer treatment using standardized criteria. Assesses anemia, neutropenia, thrombocytopenia, and other blood disorders according to laboratory values and clinical presentations.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.

Formula & Variables:

Grade assignment based on laboratory values compared to standardized thresholds for each adverse event type according to CTCAE v5.0 criteria

Input Parameters

NameTypeRequiredDescription
adverse_event_typestringYesType of hematologic adverse event to grade
hemoglobinfloatNoHemoglobin level (g/dL) - required for anemia grading(g/dL)
neutrophil_countfloatNoAbsolute neutrophil count (ANC) in cells/mm³ or x10⁹/L - required for neutropenia/febrile neutropenia grading(cells/mm³)
platelet_countfloatNoPlatelet count in cells/mm³ or x10⁹/L - required for thrombocytopenia grading(cells/mm³)
wbc_countfloatNoWhite blood cell count in cells/mm³ or x10⁹/L - required for leukocytosis grading(cells/mm³)
lymphocyte_countfloatNoAbsolute lymphocyte count in cells/mm³ or x10⁹/L - required for lymphopenia grading(cells/mm³)
temperaturefloatNoBody temperature in Celsius - required for febrile neutropenia grading(°C)
patient_sexstringYesPatient biological sex for determining normal ranges
transfusion_indicatedstringNoWhether transfusion is clinically indicated - helps determine anemia grade 3

Score Interpretation & Guidance

RangeStageDescription
0–0Grade 0Within normal limits
1–1Grade 1Mild adverse event
2–2Grade 2Moderate adverse event
3–3Grade 3Severe adverse event
4–4Grade 4Life-threatening adverse event
5–5Grade 5Death

Evidence-Based References (EBM)

  • National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
  • Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021 Feb;112(2):90-92.
  • Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.

Related calculators